Amoryn supplement claims review
This article was originally published in The Tan Sheet
Bioneurix provides a reasonable basis for general performance claims for its Amoryn dietary supplement in treating mild to moderate depression, however, evidence presented by the marketer does not support claims that the product's main ingredient, hyperforin, has been clinically proven to treat "severe" depression, according to the Electronic Retailing Self-Regulation Program. The Council of Better Business Bureaus program commenced the review of online claims as part of its ongoing monitoring efforts. Costa Mesa, Calif.-based Bioneurix said it would take the recommendations into consideration for future ads and has already taken steps to change some wording on its Web site
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.